[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638533":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":60,"collaborators":12,"id":64,"slug":12,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":12,"enrollmentInfo":72,"targetDuration":12,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":85,"whyStopped":12,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Unidade Local de Saude do Nordeste","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional therapy","NO_INTERVENTION","Conventional therapy to ACLF",null,{"label":14,"type":15,"description":16,"interventionNames":17},"DPMAS plus Plasma exchange","EXPERIMENTAL","Patients in this arm will be submitted to:\n\nDPMAS: selective adsorption therapy; mainly removes bilirrubin and inflammatory mediators AND Half-dose plasma exchange: nonselective plasma removal and replacement by a donor",[18],"Device: DPMAS plus plasma exchange",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","DPMAS plus plasma exchange","Use of extracorporal technique to support patients with acute on chronic liver failure",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Tiago B Loza, Graduated Physician","CONTACT","00351 913013068","tiago.loza@ulsne.min-saude.pt",[32],{"facility":33,"status":12,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Unidade Hospitalar de Bragança","Bragança","Braganza District","5301-852","Portugal",{"type":39,"coordinates":40},"Point",[41,42],-6.75898,41.80716,{"lat":42,"lon":41},[45,49,52,54,56,58],{"name":46,"role":28,"phone":47,"phoneExt":48,"email":30},"Tiago B Loza, Consultant Physician","913013068","00351",{"name":50,"role":51,"phone":12,"phoneExt":12,"email":12},"Carla Gomes","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":12,"phoneExt":12,"email":12},"Antonio Grilo Novais",{"name":55,"role":51,"phone":12,"phoneExt":12,"email":12},"Carla Pires",{"name":57,"role":51,"phone":12,"phoneExt":12,"email":12},"Raquel Leitão",{"name":59,"role":51,"phone":12,"phoneExt":12,"email":12},"Tiago Ceriz",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Tiago Bessa Gradim Loza","Main investigator","100638533",false,"NCT07593638","Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF","Phoenix","Inclusion Criteria:\n\n* Written informed consent for participation in the study\n* Admission to the ICU with a diagnosis of ACLF of reversible etiology (infection, bleeding, alcohol-related, toxic, etc.)\n* Total bilirubin ≥ 12 mg\u002FdL and INR ≥ 1.5\n* On the waiting list for liver transplantation or not a candidate for transplantation but with an indication for supportive therapy\n\nExclusion Criteria:\n\n* Refusal to provide consent\n* Pregnancy\n* Expected survival \\\u003C 24 hours due to disease severity (hemodynamic instability requiring norepinephrine \\> 0.20 mcg\u002Fkg\u002Fmin and\u002For mechanical ventilation with PaO₂\u002FFiO₂ \\\u003C 150 and\u002For non-hepatic coma)\n* ACLF severity greater than CLIF-C ACLF grade 3\n* Advanced organ dysfunction: Pulmonary (GOLD stage 3 or 4) and\u002For Cardiac (NYHA functional class III or IV)\n* Advanced or metastatic oncological disease (life expectancy \\\u003C 6 months)\n* Marked frailty syndrome or secondary sarcopenia\n* Participation in another clinical trial within the previous 3 months","ALL","18 Years",{"count":73,"type":74},240,"ESTIMATED","INTERVENTIONAL",[77],"NA","Clinical trial\n\nThe goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are:\n\n* Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant\n* What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery\n\nParticipants will:\n\n* Be submitted to DPMAS plus half dose plasma exchange daily according to protocol.\n* Monitoring will be continuous in the ICU",[80],"Acute on Chronic Liver Failure (ACLF)",[82,83,84],"DPMAS","Plasma exchange","ACLF","NOT_YET_RECRUITING","2026-05-11",{"date":88,"type":89},"2026-05-18","ACTUAL",{"date":91,"type":74},"2026-07",{"date":93,"type":74},"2028-01",{"name":5,"class":6},1]